Insulet's (PODD) Next-Gen OmniPod Receives FDA 510(k) Clearance

Insulet Corporation (Nasdaq: PODD) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation OmniPod Insulin Management System. The new OmniPod insulin pump is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same 200-unit insulin reservoir capacity and easy-to-use features. In addition to the smaller, lighter Pod, the new OmniPod System includes an updated Personal Diabetes Manager (PDM) that also features a series of enhancements.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• 374Water Inc (SCWO) Appoints Chris Gannon as CEO
• Edgewise Therapeutics Inc. (EWTX) Granted EU Orphan Drug Designations for Sevasemten